Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB623 in Chronic Stable Ischemic Stroke
NCT01287936Phase 2Completed
- Sponsor
- SanBio
- Start
- Jan 2011
- Primary completion
- Aug 2015
- Modality
- Gene Editing, Gene Silencing, Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of vandefitemcel in ischemic stroke, sponsored by SanBio. Started Jan 2011; status: completed.
02
Drugs
vandefitemcel
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT01287936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01287936.